MX383975B - Derivado de anillo fusionado como inhibidor del receptor a2a - Google Patents

Derivado de anillo fusionado como inhibidor del receptor a2a

Info

Publication number
MX383975B
MX383975B MX2020003732A MX2020003732A MX383975B MX 383975 B MX383975 B MX 383975B MX 2020003732 A MX2020003732 A MX 2020003732A MX 2020003732 A MX2020003732 A MX 2020003732A MX 383975 B MX383975 B MX 383975B
Authority
MX
Mexico
Prior art keywords
fused ring
receptor inhibitor
ring derivative
receptor
compound
Prior art date
Application number
MX2020003732A
Other languages
English (en)
Other versions
MX2020003732A (es
Inventor
Boyu Hu
Kai Zhou
CHEN Kevin X
Minliang Xiao
Shuhui Chen
Original Assignee
Cstone Pharmaceuticals Suzhou Co Ltd
Cstone Pharmaceuticals
Cstone Pharmaceuticals Shanghai Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cstone Pharmaceuticals Suzhou Co Ltd, Cstone Pharmaceuticals, Cstone Pharmaceuticals Shanghai Co Ltd filed Critical Cstone Pharmaceuticals Suzhou Co Ltd
Publication of MX2020003732A publication Critical patent/MX2020003732A/es
Publication of MX383975B publication Critical patent/MX383975B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Se describen un compuesto representado por la fórmula (I) o una sal farmacéuticamente aceptable de este, y una aplicación del compuesto o sal en la preparación de fármacos para tratar enfermedades relacionadas con un receptor A2A.
MX2020003732A 2017-09-28 2018-09-27 Derivado de anillo fusionado como inhibidor del receptor a2a MX383975B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201710900542 2017-09-28
CN201810239824 2018-03-21
PCT/CN2018/107899 WO2019062803A1 (zh) 2017-09-28 2018-09-27 作为a2a受体抑制剂的并环类衍生物

Publications (2)

Publication Number Publication Date
MX2020003732A MX2020003732A (es) 2021-06-29
MX383975B true MX383975B (es) 2025-03-14

Family

ID=65900821

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020003732A MX383975B (es) 2017-09-28 2018-09-27 Derivado de anillo fusionado como inhibidor del receptor a2a

Country Status (15)

Country Link
US (1) US11312715B2 (es)
EP (1) EP3686199B9 (es)
JP (1) JP6836693B2 (es)
KR (1) KR102254660B1 (es)
CN (1) CN111542520B (es)
AU (1) AU2018341781B2 (es)
CA (1) CA3077267C (es)
ES (1) ES2927086T3 (es)
IL (1) IL273606B (es)
MX (1) MX383975B (es)
RU (1) RU2748993C1 (es)
SA (1) SA520411635B1 (es)
SG (1) SG11202002886PA (es)
TW (1) TWI788424B (es)
WO (1) WO2019062803A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110655509B (zh) * 2018-06-29 2023-01-24 江苏恒瑞医药股份有限公司 2-胺基嘧啶类衍生物、其制备方法及其在医药上的应用
CN111094254B (zh) * 2018-07-12 2022-07-26 江苏恒瑞医药股份有限公司 杂芳基类衍生物、其制备方法及其在医药上的应用
CN111377873B (zh) * 2018-12-28 2023-03-28 四川科伦博泰生物医药股份有限公司 氨基嘧啶化合物及其制备方法和用途
WO2020192762A1 (zh) * 2019-03-28 2020-10-01 基石药业（苏州）有限公司 一种a2a受体拮抗剂的盐型、晶型及其制备方法
JP7584623B2 (ja) * 2020-07-23 2024-11-15 シトシンラボ セラピューティクス カンパニー， リミテッド キナーゼ阻害活性を有する化合物
CN116514803A (zh) * 2022-01-21 2023-08-01 上海赛岚生物科技有限公司 一种激酶抑制剂的盐晶型和自由碱晶型

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100283363B1 (ko) 1995-04-21 2001-03-02 페더 벨링 벤즈이미다졸 화합물 및 감마-아미노부틸산 수용체 복합체의 조절인자로 그들의 용도
CA2284737C (en) * 1997-03-24 2007-03-13 Kyowa Hakko Kogyo Co., Ltd. [1,2,4]triazolo[1,5-c]pyrimidine derivatives
CZ2003182A3 (cs) 2000-06-21 2003-06-18 F. Hoffmann-La Roche Ag Deriváty benzothiazolu
EP1308441B1 (en) * 2000-08-11 2009-10-07 Eisai R&D Management Co., Ltd. 2-aminopyridine compounds and use thereof as drugs
MXPA06011236A (es) * 2004-04-02 2007-01-16 Prana Biotechnology Ltd Compuestos neurologicamente activos.
ES2241496B1 (es) 2004-04-15 2006-12-01 Almirall Prodesfarma, S.A. Nuevos derivados de piridina.
ES2274712B1 (es) 2005-10-06 2008-03-01 Laboratorios Almirall S.A. Nuevos derivados imidazopiridina.
EP1903044A1 (en) 2006-09-14 2008-03-26 Novartis AG Adenosine Derivatives as A2A Receptor Agonists
HUE025704T2 (en) 2009-03-20 2016-04-28 Sigma Tau Ind Farmaceuti Oxidized triazolyl purine derivatives used as adenosine A2A receptor ligands and their use as medicaments
DE102012019369A1 (de) * 2012-10-02 2014-04-03 Merck Patent Gmbh 7-Azaindolderivat
CN105025899B (zh) 2012-12-28 2017-08-18 默沙东公司 具有A2A拮抗剂性质的杂二环取代的‑[1,2,4]三唑并[1,5‑c]喹唑啉‑5‑胺化合物
WO2014101120A1 (en) * 2012-12-28 2014-07-03 Merck Sharp & Dohme Corp. Heterobicyclo-substituted-7-methoxy-[1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds with a2a antagonist properties
RU2534804C1 (ru) 2013-08-05 2014-12-10 Общество С Ограниченной Ответственностью "Ньювак" (Ооо "Ньювак") ЗАМЕЩЕННЫЕ [1,2,4]ТРИАЗОЛО[4,3-a]ПИРИДИНЫ, ПРОЯВЛЯЮЩИЕ СВОЙСТВА АНТАГОНИСТОВ АДЕНОЗИНОВЫХ А2А РЕЦЕПТОРОВ, И ИХ ПРИМЕНЕНИЕ
JP6275410B2 (ja) 2013-08-06 2018-02-07 大和ハウス工業株式会社 固定具
WO2015027431A1 (en) 2013-08-29 2015-03-05 Merck Sharp & Dohme Corp. 2,2-difluorodioxolo a2a receptor antagonists
US10407424B2 (en) * 2017-03-30 2019-09-10 Genentech, Inc. Naphthyridines as inhibitors of HPK1

Also Published As

Publication number Publication date
CN111542520A (zh) 2020-08-14
EP3686199B9 (en) 2022-12-07
ES2927086T3 (es) 2022-11-02
AU2018341781A8 (en) 2020-05-07
CN111542520B (zh) 2022-04-15
TWI788424B (zh) 2023-01-01
AU2018341781B2 (en) 2023-03-30
EP3686199A4 (en) 2021-04-07
CA3077267A1 (en) 2019-04-04
SA520411635B1 (ar) 2022-05-24
EP3686199A1 (en) 2020-07-29
US20200239465A1 (en) 2020-07-30
US11312715B2 (en) 2022-04-26
JP6836693B2 (ja) 2021-03-03
RU2748993C1 (ru) 2021-06-02
KR102254660B1 (ko) 2021-05-24
EP3686199B1 (en) 2022-08-03
AU2018341781A1 (en) 2020-04-30
IL273606A (en) 2020-05-31
KR20200055126A (ko) 2020-05-20
MX2020003732A (es) 2021-06-29
TW201920171A (zh) 2019-06-01
WO2019062803A1 (zh) 2019-04-04
JP2020535196A (ja) 2020-12-03
SG11202002886PA (en) 2020-04-29
BR112020006185A2 (pt) 2020-10-13
IL273606B (en) 2021-05-31
CA3077267C (en) 2021-02-16

Similar Documents

Publication Publication Date Title
CL2020000886A1 (es) Derivados de 1-benzil-2-imino-4-fenil-5-oxoimidazolidina como inhibidores de la proteasa del vih.
CL2019001744A1 (es) Derivados de benzoxazol como inmunomoduladores.
ECSP20033467A (es) Compuestos macrocíclicos para tratar enfermedades
CY1123059T1 (el) Αναστολη του διαυλου ιοντων παροδικου δυναμικου του υποδοχεα α1
NI201700096A (es) Derivados de 4h-pirrol[3, 2-c]piridin-4-ona
MX383975B (es) Derivado de anillo fusionado como inhibidor del receptor a2a
MX2020007265A (es) Derivados de rapamicina.
UY37124A (es) Nuevos compuestos de 6,7-dihidro-5h-benzo[7]anuleno sustituidos, procesos para su preparación y usos terapéuticos de los mismos
UA117958C2 (uk) Похідні хіноксаліну, корисні як модулятори кінази fgfr
MX372914B (es) Derivado de piperidina y metodo de preparacion y uso farmaceutico del mismo.
BR112016029612A2 (pt) compostos de di-hidroisoquinolinona substituídos
MX374443B (es) Nuevos derivados piperidinilo sustituidos con hetero(arilo), un proceso para su preparacion y composiciones farmaceuticas que los contienen
MX373373B (es) Inhibidores de desmetilasa-1 específica de lisina.
EA201990833A1 (ru) Соединение пиридина
EA201691988A1 (ru) Производные бороновой кислоты и их терапевтическое применение
EA201591612A1 (ru) ПРИМЕНЕНИЕ ПИРАЗОЛПИРИМИДИНОВЫХ ПРОИЗВОДНЫХ ДЛЯ ЛЕЧЕНИЯ НАРУШЕНИЙ, СВЯЗАННЫХ С PI3Kδ
EA201790395A1 (ru) Производные аминотриазина, подходящие для применения в качестве соединений-ингибиторов tank-связывающей киназы
MX375099B (es) Derivados de aminotiazol útiles como agentes antivíricos.
MX2021005052A (es) Oxiesteroles y métodos de uso de los mismos.
EA201791058A1 (ru) Морфолин- и 1,4-оксазепан-амиды в качестве агонистов соматостатинового рецептора подтипа 4 (sstr4)
SV2017005381A (es) Compuestos de imidazopiridazina
UY35906A (es) Novedosos derivados de bencimidazol como ligandos de ep4
MX382313B (es) Derivados del sobetiroma.
MX2016012784A (es) Composiciones farmaceuticas solidas que comprenden derivados de biopterina y usos de tales composiciones.
ECSP19013196A (es) Derivado de triazolopirazinona útil como un inhibidor de pde1 humana